We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The mean affected BSA decreased from 58% at baseline to ...

Credit: Getty Images. The NDA submission also includes data from the 44-week, open-label, long term extension of both trials. The Food and Drug Administration (FDA) has accepted for Priority Review ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Four of 589 adverse events were serious and included ...

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023. Compared with other ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announces positive 52-week results from its randomized, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a ...

The application is supported by data from the phase 3 TRuE-V clinical trial program. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application for ...

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...

On Saturday, Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of ...

BID, twice daily; F-PhGVA, facial Physician’s Global Vitiligo Assessment; F-VASI, facial Vitiligo Area Scoring Index; F-VASI50/75/90, ≥50%/≥75%/≥90% ...

Phase 3 trials of Incyte’s ruxolitinib cream in patients with vitiligo have met their primary endpoints. The success of the topical JAK inhibitor tees Incyte up to seek approval in the U.S. and Europe ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) ...

- Treatment with ruxolitinib cream (Opzelura™) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving ≥75% improvement from baseline in the ...